A randomized phase II study of paclitaxel (P), carboplatin (C), bevacizumab (B) +/- everolimus (E) in metastatic melanoma (MM): secondary analysis of outcomes in patients who harbor an NRAS mutation NCCTG N0879 (Alliance).
- Citation:
- Meeting Instance:
- SMR 2017
- Year:
- 2017
- Type:
- Abstract
- Sub type:
- Poster General
- Funding:
- NCTN
- Endpoint:
- Secondary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- None
- Program:
- OGC
- Primary Committee:
- Experimental
- Sec. Committees:
- Pharmas:
- Grants:
- U10CA180821, U10CA180882
- Corr. Author:
- Authors:
- Lisa Kottschade Jacob Allred K. Rumila Svetomir Markovic Matthew Block Robert McWilliams
- Networks:
- LAPS-MN026
- Study
- NCCTG-N0879
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords: